Telix Pharmaceuticals (TLX) began trading on the Nasdaq on Thur 14 Nov 24

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. 

• Sector: Healthcare
• Industry: Biotechnology
• Founded by Andreas Kluge and Christian P. Behrenbruch in 2015 
• Headquartered in Melbourne, Australia
• https://telixpharma.com

Septerna (SEPN) began trading on the Nasdaq on Fri 25 Oct 24

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. 

Septerna was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 68
• Incorporated in 2019 
• Headquartered in South San Francisco, California
• https://septerna.com

Septerna opened at $23.50 after pricing 16.0 mln share IPO at $18/share, above the $15-17 expected range

Septerna, a clinical-stage pharmaceutical company with an initial focus on rare endocrine diseases, draws strong interest for its IPO

• After pricing its upsized 16.0 mln share IPO at $18, above the $15-$17 expected price range, Septerna (SEPN) opened for trading at $23.50, good for a 31% opening gain. 
• The company has developed a proprietary "Native Complex Platform" that it believes will usher in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery. GPCRs are a family of cell membrane receptors that regulate physiological processes in nearly every organ system in the human body.
• Its lead product candidate is SEP-876, which is currently in Phase 1 studies and being evaluated for the treatment of Hypoparathyroidism -- a rare endocrine disease characterized by insufficient levels of parathyroid hormone that affects approximately 70,000 patients in the United States. The company expects to report data on the trial in mid-2025.
• Including the proceeds from this offering, SEPN has approximately $400.0 mln in cash and cash equivalents. SEPN believes that it will have enough capital to fund its operations and clinical trials into 2H27.